Industry Newsglp 1rdiabetesascletisclinical trial
Ascletis Doses First Participants With ASC30
4.0
Relevance Score
Ascletis has dosed first participants in a 13-week U.S. Phase II study of ASC30, an oral small-molecule GLP-1R agonist for diabetes; topline data are expected in the third quarter of 2026.
Scoring Rationale
Progression to Phase II indicates moderate industry relevance, but RSS-only release provides limited details and constrains impact assessment.
Sources
- Read OriginalAscletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetesmanilatimes.net
